Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT

Trial Profile

Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CARFI
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Aug 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2018 Results assessing the safety and response data on the first 118 included patients that have undergone induction and salvage ASCT, presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top